AU2020327022B2 - Method of treating cancer - Google Patents

Method of treating cancer

Info

Publication number
AU2020327022B2
AU2020327022B2 AU2020327022A AU2020327022A AU2020327022B2 AU 2020327022 B2 AU2020327022 B2 AU 2020327022B2 AU 2020327022 A AU2020327022 A AU 2020327022A AU 2020327022 A AU2020327022 A AU 2020327022A AU 2020327022 B2 AU2020327022 B2 AU 2020327022B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
daily dosage
free base
per dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020327022A
Other languages
English (en)
Other versions
AU2020327022A1 (en
AU2020327022A8 (en
Inventor
Chris Lu
Yong Yue
Minhua Zhang
Ruipeng ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laekna Ltd
Original Assignee
Laekna Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laekna Ltd filed Critical Laekna Ltd
Publication of AU2020327022A1 publication Critical patent/AU2020327022A1/en
Publication of AU2020327022A8 publication Critical patent/AU2020327022A8/en
Application granted granted Critical
Publication of AU2020327022B2 publication Critical patent/AU2020327022B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020327022A 2019-08-08 2020-08-07 Method of treating cancer Active AU2020327022B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/099754 2019-08-08
CN2019099754 2019-08-08
PCT/US2020/045410 WO2021026454A1 (en) 2019-08-08 2020-08-07 Method of treating cancer

Publications (3)

Publication Number Publication Date
AU2020327022A1 AU2020327022A1 (en) 2022-02-10
AU2020327022A8 AU2020327022A8 (en) 2022-06-30
AU2020327022B2 true AU2020327022B2 (en) 2025-12-18

Family

ID=72234946

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020327022A Active AU2020327022B2 (en) 2019-08-08 2020-08-07 Method of treating cancer

Country Status (12)

Country Link
US (2) US20210038578A1 (enExample)
EP (1) EP4009969A1 (enExample)
JP (1) JP7526783B2 (enExample)
KR (1) KR20220047589A (enExample)
CN (1) CN114080225A (enExample)
AU (1) AU2020327022B2 (enExample)
BR (1) BR112022001508A2 (enExample)
CA (1) CA3148115A1 (enExample)
IL (1) IL289811A (enExample)
MX (1) MX2022001450A (enExample)
TW (1) TWI857119B (enExample)
WO (1) WO2021026454A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7010330B1 (en) 2003-03-01 2006-03-07 Theta Microelectronics, Inc. Power dissipation reduction in wireless transceivers
EP4438046A4 (en) * 2021-11-27 2025-12-03 Transthera Sciences Nanjing Inc NEW APPLICATION OF KINASE INHIBITOR
US20250177352A1 (en) 2022-03-14 2025-06-05 Laekna Limited Combination treatment for cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180264008A1 (en) * 2013-10-01 2018-09-20 Novartis Ag Combination

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
ES2138618T3 (es) 1992-03-31 2000-01-16 Btg Int Ltd Esteroides 17-sustituidos utiles en el tratamiento del cancer.
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
BRPI0709771B1 (pt) 2006-03-27 2022-01-25 The Regents Of The University Of California Composto e composição farmacêutica
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
NZ594064A (en) * 2009-01-30 2012-08-31 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
PE20121048A1 (es) * 2009-06-26 2012-08-25 Novartis Ag Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
CA2872541A1 (en) * 2012-06-06 2013-12-12 Novartis Ag Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
CN108112235A (zh) * 2015-03-06 2018-06-01 克利夫兰临床基金会 改变类固醇代谢以用于治疗类固醇依赖性疾病

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180264008A1 (en) * 2013-10-01 2018-09-20 Novartis Ag Combination

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARIA DE SANTIS, FRED SAAD: "Practical Guidance on the Role of Corticosteroids in the Treatment of Metastatic Castration-resistant Prostate Cancer", UROLOGY., BELLE MEAD, NJ, US, vol. 96, 1 October 2016 (2016-10-01), US, pages 156 - 164, XP055745356, ISSN: 0090-4295, DOI: 10.1016/j.urology.2016.02.010 *
SEBASTIEN J. HOTTE, CARLES JOAN, SARANTOPOULOS JOHN, RYAN CHARLES, LANG JOSHUA, MONTGOMERY BRUCE, FUKINO KOICHI, GOBBO GWENDOLYN, : "Abstract B29: A multicenter, open-label phase 1/2 study of oral CFG920, in combination with prednisone in adult patients with metastatic castration-resistant prostate cancer", CLINICAL TRIALS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1 December 2015 (2015-12-01), pages B29 - B29, XP055745334, ISSN: 2194-7481, DOI: 10.1158/1535-7163.TARG-15-B29 *

Also Published As

Publication number Publication date
EP4009969A1 (en) 2022-06-15
TWI857119B (zh) 2024-10-01
JP7526783B2 (ja) 2024-08-01
US20250090514A1 (en) 2025-03-20
AU2020327022A1 (en) 2022-02-10
AU2020327022A8 (en) 2022-06-30
TW202120086A (zh) 2021-06-01
IL289811A (en) 2022-03-01
BR112022001508A2 (pt) 2022-07-12
CN114080225A (zh) 2022-02-22
JP2022543679A (ja) 2022-10-13
MX2022001450A (es) 2022-04-20
US20210038578A1 (en) 2021-02-11
KR20220047589A (ko) 2022-04-18
CA3148115A1 (en) 2021-02-11
WO2021026454A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
US20250090514A1 (en) Method of treating cancer
RU2318517C2 (ru) Комбинация, включающая n-{5-[4-(4-метилпиперазинометил)бензоиламидо]-2-метилфенил}-4-(3-пиридил)-2-пиримидинамин и химиотерапевтический агент
JP2023145689A (ja) Ｈｅｒ２陽性がんの処置
AU2019324155A1 (en) Platelet count-agnostic methods of treating myelofibrosis
US20240180906A1 (en) Combination of Talazoparib and an Anti-Androgen for the Treatment of DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer
KR20210106484A (ko) Hdm2-p53 상호작용 억제제와 bcl2 억제제의 조합 및 암 치료를 위한 이의 용도
JP2020530026A (ja) 線維性疾患の治療における使用のための化合物及びその医薬組成物
JP2022553041A (ja) Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
EA049014B1 (ru) Способ лечения рака
US20210046106A1 (en) Methods of treating cancer with androgen deprivation therapy in combination with an inhibitor of the sp1 transcription factor
US20240335440A1 (en) Combination therapy comprising a pkc inhibitor and a c-met inhibitor
US11723898B2 (en) Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
AU2023356291A1 (en) Methods of treating estrogen receptor-mediated disorders
CA3269490A1 (en) Methods of treating estrogen receptor-mediated disorders
AU2024259627A1 (en) Methods of treating hepatic-only metastatic uveal melanoma
KR20240148328A (ko) 전이성 거세 저항성 전립선암 및 hrr 변형을 갖는 환자에서 임상 결과를 개선하기 위한 니라파립 및 아비라테론 아세테이트와 프레드니손
TW202339748A (zh) 使用經取代之嘧啶-4(3h)-酮之治療方法
HK40087811A (en) Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
HK1204976A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
HK1204976B (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 36 , NO 6 , PAGE(S) 775 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME LAEKNA LIMITED, APPLICATION NO. 2020327022, UNDER INID (72) CORRECT THE CO-INVENTOR TO YUE, YONG

FGA Letters patent sealed or granted (standard patent)